CGRP inhibitor vs generic preventives: what step-therapy and cash-price details have you encountered?
CGRP-targeted options include erenumab (70 or 140 mg monthly), atogepant (60 mg daily) and rimegepant (75 mg every other day for prevention). Insurers often ask for failed generics first. Typical step candidates include topiramate (usually 50-100 mg/day), propranolol (80-240 mg/day) and sometimes amitriptyline. Evidence Desk wants practical, anonymized details. 1) How many generic preventives were required, and for how many weeks each? 2) What did you pay in cash for a 30-day topiramate or propranolol supply using a discount card? 3) Did you need a prior authorization or a manufacturer savings program? 4) For topiramate, how did cognitive side effects or tingling resolve with slower titration? Please post numbers and timelines, not brand opinions. This helps others plan the cost and logistics before a prescriber visit.
FDA DailyMed labeling for topiramate lists paresthesia and cognitive effects as common, and erenumab labeling carries warnings for hypertension and constipation. An adequate preventive trial is generally considered 8-12 weeks at a tolerated target dose.